Table 1.
Characteristics | Donors (n = 23) | SP (n = 13) | PV (n = 22) | ET (n = 38) | PMF (n = 9) | ||
---|---|---|---|---|---|---|---|
JAK2WT/V617F (n = 0) (n = 22; 100 %) | JAK2WT/V617F (n = 9; 19.5 %) (n = 29; 80.5 %) | JAK2WT/V617F (n = 4) (n = 5) | |||||
Age, median (years) (range) |
45 (26–61) |
59 (27–90) |
65 (52–88) |
63 (35–80) |
62 (38–81) |
75 (70–80) |
68 (47–83) |
Gender, male/female | 16/7 | 13/0 | 17/5 | 4/5 | 20/29 | 2/4 | 3/5 |
Hb (g/dl), median (range) |
15 (11.5–16.9) |
17 (16–18.2) |
18 (17.6–20.2) |
12.5 (11.6–14) |
15 (12–19) |
9.6 (8.9–10) |
15.4 (13.8–17.3) |
WBC (1 × 109/l), median (range) |
6.6 (4.7–9.3) |
7.1 (4.8–11.4) |
10.6 (4.4–15) |
8.5 (6–10) |
9.9 (7.1–18) |
8 (1.3–16.8) |
20.6 (20–10.8) |
PLTs (1 × 109/l), median (range) |
232 (192–349) |
200.5 (91–274) |
370 (75–712) |
792 (631–1,420) |
718 (256–1,318) |
364 (129–489) |
555 (197–946) |
Neutrophils (1 × 109/l), median (range) |
4.4 (1.4–7) |
4.6 (1.4–7.5) |
7.9 (2.7–13) |
4.6 (2.8–7.6) |
6 (1.4–13.5) |
5.1 (1–9.4) |
15.9 (8.4–19.5) |
JAK2WT copy numbers (1 × 103), median (range) |
7.7 (1.2–38.5) |
8.7 (2.5–30.9) |
6.9 (0.02–22.6) |
15.6 (6.2–34.5) |
6.0 (0.9–16.7) |
11.2 (3.8–18.5) |
3.0 (0.3–4.5) |
JAK2V617F copy numbers (1 × 103), median (range) |
– | – |
26.9 (0.2–203.6) |
– |
6.9 (0.7–52.8) |
– |
29.4 (1.4–78.7) |
ABL1 copy number (1 × 103), median (range) |
4.6 (1.6–11.9) |
5.0 (2.4–20.6) |
2.9 (0.9–12.7) |
7.4 (1.8–17.7) |
3.8 (0.3–8.7) |
8.6 (4.6–14.9) |
3.3 (1.7–4.6) |
B2M copy number (1 × 106), median (range)a |
8.0 (2.8–10.1) |
4.8 (2.5–13.0) |
8.8 (2.4–17.7) |
6.1 (2.4–7.9) |
8.1 (2.4–17.3) |
6.0 |
7.0 (2.3–13.4) |
GUSB copy number (1 × 103), median (range)a |
37.6 (7.4–53.2) |
34.5 (3.2–58.7) |
37.8 (0.2–56.7) |
39.8 (8.6–71.6) |
33.2 (5.8–59.1) |
23.4 |
41.0 (19.3–93.5) |
a B2M and GUSB copy numbers were detected in donor (n = 11), SP (n = 5), PV (n = 16), ET (WT n = 7; V617F n = 24), and PMF (WT n = 1; V617F n = 4) samples